ClinicalTrials.gg
CompletedNCT02589275Updated Feb 20, 2025Results posted

A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients

A Phase 3 interventional study of TNX-102 SL Tablet 2.8 mg in Primary Fibromyalgia, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 33 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Enrollment
43rd of 320
375 · median 72
Started
2015
with 11 others
Phase 3
55 of 369
2 open now
Registered
210th of 369
by date
Lead sponsor
8 of 369
Tonix Pharmaceuticals, Inc.

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 43rd largest by enrollment of the 320 interventional ones that give a count, is one of 12 that started in 2015, is one of 55 in phase 3, and was the 210th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, open-label, extension trial designed to evaluate the long term safety and efficacy over 3 months of TNX-102 SL tablets taken daily at bedtime for the treatment of Fibromyalgia (FM). Patients recruits into this trial are those who have successfully completed the double-blind studies; TNX-CY-F301 and TNX-CY-F302.

Patients will not be made aware of the therapy they received during the double-blind study.

Read the detailed description

The study consist of 4 study visits, including Screening/Baseline Visit 1 (Day 1, which is anticipated to be the same date as Visit 6 in F301 or F302) and visits after 1, 2 and 3 months of treatment (Visits 2-4).

Primary:

The primary objective of the study is to evaluate the safety of TNX-102 SL tablets taken daily at bedtime over an additional 3 months in patients with FM who have completed the double-blinded lead-in study

Secondary:

The secondary objective is to evaluate the efficacy of TNX-102 SL tablets taken daily at bedtime to control symptoms of FM

03

Conditions studied

  • Primary Fibromyalgia

Browse trials for

Keywords

  • TNX-102 SL
  • bedtime
  • sublingual
  • 3-month
  • long term safety
  • long term efficacy
  • Fibromyalgia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient met all prior inclusion and exclusion requirements for study F301 or F302 originally, and has had no intervening medical conditions, increased suicidal ideation, or requirements for concomitant medications that preclude exposure to TNX-102 SL or enrollment in the extension study.
  • The patient completed expected dosing in F301 or F302 defined as taking study medication up to Week 12, with at least 70% compliance with medication usage (based on overall drug accountability reconciliation at the end of the F301 or F302 lead-in study) and no major protocol deviations.
  • The patient has provided written to participate in this extension protocol.

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    TNX-102 SL Tablet 2.8 mg

    1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 3 months

    Drug: TNX-102 SL Tablet 2.8 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Newly Emergent Adverse Events

    The number of patients with at least one adverse event which began after the first dose of TNX-102 SL in this open-label extension study.

    Time frame: Up to 3 months from first dose

07

Results

Posted Dec 11, 2024

Participant flow

Participant flow — Overall Study
MilestoneTNX-TNXPBO-TNX
Started177198
Completed143142
Not completed3456

Outcome measures

PrimaryNewly Emergent Adverse Events

The number of patients with at least one adverse event which began after the first dose of TNX-102 SL in this open-label extension study.

Time frame:
Up to 3 months from first dose
Reported as:
Count of participants · Participants
Newly Emergent Adverse Events
ParticipantsTNX-TNXPBO-TNX
Newly Emergent Adverse Events77132

Adverse events

Collected over Up to 3 months from first dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TNX-TNX0/177 (0%)2/170 (1.2%)69/170 (40.6%)
PBO-TNX0/198 (0%)0/186 (0%)86/186 (46.2%)
Most frequent serious events
Most frequent serious events
EventTNX-TNXPBO-TNX
LymphadenopathyBlood and lymphatic system disorders1/1700/186
Chronic sinusitisInfections and infestations1/1700/186
Ovarian cystReproductive system and breast disorders1/1700/186
Most frequent other events
Most frequent other events
EventTNX-TNXPBO-TNX
Hypoaesthesia OralGastrointestinal disorders60/17073/186
Product Taste AbnormalProduct Issues9/17020/186
Tongue DiscomfortGastrointestinal disorders5/17015/186
Parasthesia OralGastrointestinal disorders9/17011/186

Baseline characteristics

Age, Continuous
Age, Continuous(years)TNX-TNXPBO-TNXTotal
Mean48.2 ± 11.3548.0 ± 10.7748.1 ± 11.03
Sex: Female, Male
Sex: Female, Male(Participants)TNX-TNXPBO-TNXTotal
Female169191360
Male8715
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TNX-TNXPBO-TNXTotal
American Indian or Alaska Native224
Asian145
Native Hawaiian or Other Pacific Islander101
Black or African American61925
White166172338
More than one race112
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)TNX-TNXPBO-TNXTotal
United States177198375
08

Study locations

33 sites
  • Birmingham, Alabama 35216, United States
  • Phoenix, Arizona 85032, United States
  • Sacramento, California 95825, United States
  • San Diego, California 92103, United States
  • Brandon, Florida 33511, United States
  • DeLand, Florida 32720, United States
  • Lakeland, Florida 33805, United States
  • Ocala, Florida 34471, United States
  • Orlando, Florida 32806, United States
  • Tampa, Florida 33614, United States
  • West Palm Beach, Florida 33409, United States
  • Columbus, Georgia 31904, United States
  • Smyrna, Georgia 30080, United States
  • Evansville, Indiana 47714, United States
  • North Dartmouth, Massachusetts 02747, United States
  • Ann Arbor, Michigan 48104, United States
  • Jackson, Mississippi 39202, United States
  • Williamsville, New York 14221, United States
  • Cincinnati, Ohio 45206, United States
  • Middleburg Heights, Ohio 44130, United States
  • Medford, Oregon 97504, United States
  • Portland, Oregon 97210, United States
  • Allentown, Pennsylvania 18104, United States
  • Warwick, Rhode Island 02888, United States
  • Greer, South Carolina 29650, United States
  • Mount Pleasant, South Carolina 29464, United States
  • Dallas, Texas 75231, United States
  • Salt Lake City, Utah 84102, United States
  • Charlottesville, Virginia 22911, United States
  • Norfolk, Virginia 23507, United States
  • Bellevue, Washington 98007, United States
  • Seattle, Washington 98104, United States
  • Kenosha, Wisconsin 53142, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Sep 2016, 13 months.

Results were first posted in Dec 2024, 8 years 2 months after primary completion. A results delay was requested in Apr 2018.

Of 17 phase 3 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2015
First posted
Oct 28, 2015
StartActual
Aug 4, 2015
Primary completionActual
Sep 28, 2016
CompletionActual
Sep 28, 2016
Results delay requested
Apr 23, 2018
Results first posted
Dec 11, 2024
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02589275
Responsible party
Sponsor
First posted
Oct 28, 2015
Start date
Aug 4, 2015
Primary completion
Sep 28, 2016
Completion
Sep 28, 2016
Results posted
Dec 11, 2024
Last update
Feb 20, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion